<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975195</url>
  </required_header>
  <id_info>
    <org_study_id>352.2046</org_study_id>
    <secondary_id>2007-002522-29</secondary_id>
    <nct_id>NCT00975195</nct_id>
  </id_info>
  <brief_title>Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a randomised study to be conducted in patients with severe to very severe Chronic
      Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients
      to be continuously treated with an inhaled corticosteroid on top of two potent long-acting
      bronchodilators. The study also aims to identify the type of patients who are likely to
      benefit from inhaled corticosteroid maintenance therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Moderate or Severe On-treatment COPD Exacerbation</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as an increase or new onset of ≥2 lower respiratory symptoms related to COPD, with ≥1 symptom lasting ≥3 days, requiring a change in treatment. Lower respiratory symptoms included shortness of breath, sputum production (volume), sputum purulence, cough, wheezing and chest tightness. A change in treatment included: hospitalisation/treatment in an urgent care unit, prescription of antibiotics and/or systemic steroids or a significant change of prescribed respiratory medication such as theophyllines, long-acting beta-agonists or inhaled corticosteroids. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Moderate or Severe On-treatment COPD Exacerbations</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Number of moderate or severe on-treatment COPD exacerbations, based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined and counted as moderate or severe if ≥1 of the contributing exacerbation events was moderate or severe. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital. Exacerbations were considered moderate if they required prescription of antibiotics and/or systemic steroids.
Measured values show adjusted mean event rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With ≥1 Moderate or Severe On-treatment COPD Exacerbation</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Presence (yes vs no) of at least one moderate or severe on-treatment COPD exacerbation, displayed as a percentage. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital. Exacerbations were considered moderate if they required prescription of antibiotics and/or systemic steroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Severe On-treatment COPD Exacerbation</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Time to first severe on-treatment COPD exacerbation. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.
The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Severe On-treatment COPD Exacerbations</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Number of severe on-treatment COPD exacerbations based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined and counted as severe if ≥1 of the contributing exacerbation events was severe. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.
Measured values show adjusted event rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With at Least One Severe On-treatment COPD Exacerbation.</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Presence (yes vs no) of at least one severe on-treatment COPD exacerbation, displayed as a percentage. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First On-treatment COPD Exacerbation</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Time to first on-treatment COPD exacerbation of any severity. The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of On-treatment COPD Exacerbations</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Number of on-treatment COPD exacerbations of any severity, based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined.
Measured values show adjusted event rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With at Least One On-treatment COPD Exacerbation</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Presence (yes vs no) of at least one on-treatment COPD exacerbation of any severity, displayed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of On-treatment COPD Exacerbations</measure>
    <time_frame>During randomised treatment, up to 488 days</time_frame>
    <description>Severity of on-treatment COPD exacerbations: for each patient, the worst applicable category was taken (i.e. none, mild, moderate or severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment Lung Function as Measured by Trough FEV1</measure>
    <time_frame>Baseline and week 6, 12, 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment lung function as measured by trough forced expiratory volume in one second (FEV1); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in On-treatment Dyspnoea as Measured by the Modified Medical Research Council (MMRC) Dyspnoea Scale</measure>
    <time_frame>Baseline and week 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment dyspnoea as measured by the Modified Medical Research Council (MMRC) dyspnoea scale; change was calculated as week score minus baseline score. Negative changes from baseline indicate an improvement in health.
Scale from 0 to 4:
0 = not troubled by breathlessness, except during strenuous exercise
1 = short of breath when hurrying or walking up a slight hill
2 = walks slower than contemporaries on the same level because of breathlessness, or has to stop for breath when walking at own pace
3 = stops for breath after approximately 100 yards, or after a few minutes on the level
4 = too breathless to leave the house, or breathless when dressing or undressing
&quot;No breathlessness&quot; was given a score of -1
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment Physical Health Status as Determined by Body Mass Index (BMI)</measure>
    <time_frame>Baseline and week 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment physical health status as determined by body mass index (BMI); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment Exercise Capacity Measured by Six-minute Walk Test (6-MWT)</measure>
    <time_frame>Baseline and week 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment exercise capacity measured by six-minute walk test (6-MWT); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment BODE Index</measure>
    <time_frame>Baseline and week 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment BODE index (Body mass index, airflow Obstruction, Dyspnea and Exercise capacity index), a composite score ranging from 0 (best) to 10 (worst); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Cough Impact Domain</measure>
    <time_frame>Baseline and week 12, 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Cough impact domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from &quot;not at all/never&quot; to &quot;extremely/always&quot; on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less impact due to cough.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Cough Symptoms Domain</measure>
    <time_frame>Baseline and week 12, 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Cough symptoms domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from &quot;not at all/never&quot; to &quot;a lot/always&quot; on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less symptoms due to cough.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Sputum Impact Domain</measure>
    <time_frame>Baseline and week 12, 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Sputum impact domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from &quot;not at all/never&quot; to &quot;a lot/always&quot; on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less impact due to sputum.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Sputum Symptoms Domain</measure>
    <time_frame>Baseline and week 12, 18 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Sputum symptoms domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from &quot;not at all/never&quot; to &quot;extremely/always&quot; on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less symptoms due to sputum.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment FEV1 as Measured by Home Based Spirometry</measure>
    <time_frame>Baseline and week 6, 12, 18, 27, 36, 45 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment Forced Expiratory Volume in One Second (FEV1) as measured by home based spirometry. Change was calculated as week score minus baseline score. The weekly mean was defined as the mean of the measurements taken during the last 7 days prior to the visit date, and was calculated if ≥4 of the 7 days had non-missing measurements. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment FVC as Measured by Home Based Spirometry</measure>
    <time_frame>Baseline and week 6, 12, 18, 27, 36, 45 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment forced vital capacity (FVC) as measured by home based spirometry. Change was calculated as week score minus baseline score. The weekly mean was defined as the mean of the measurements taken during the last 7 days prior to the visit date, and was calculated if ≥4 of the 7 days had non-missing measurements. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment PEFR as Measured by Home Based Spirometry</measure>
    <time_frame>Baseline and week 6, 12, 18, 27, 36, 45 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment peak expiratory flow rate (PEFR) as measured by home based spirometry; change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Activity Domain</measure>
    <time_frame>Baseline and week 27 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Activity domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Impact Domain</measure>
    <time_frame>Baseline and week 27 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Impact Domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Symptoms Domain</measure>
    <time_frame>Baseline and week 27 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Symptoms domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Total Score</measure>
    <time_frame>Baseline and week 27 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Total score. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in On-treatment Physician Global Evaluation</measure>
    <time_frame>Baseline and week 27 and 52 visits</time_frame>
    <description>Change from baseline in on-treatment physician global evaluation. The evaluation reflected the physician's opinion of the patient's overall condition and was based on the need for concomitant medication, the number and severity of exacerbations, the severity of cough, the ability to exercise, the amount of wheezing and any other relevant clinical observations. Patients were graded on a scale of 1 (poor) to 8 (excellent). Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2488</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>fluticasone high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluticasone medium &amp; low doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone priopionate medium and high doses; and tiotropium inhalation; and salmeterol xinafoate; and placebo matched to fluticasone priopionate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium inhalation</intervention_name>
    <arm_group_label>fluticasone high dose</arm_group_label>
    <arm_group_label>fluticasone medium &amp; low doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol xinafoate</intervention_name>
    <arm_group_label>fluticasone high dose</arm_group_label>
    <arm_group_label>fluticasone medium &amp; low doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <arm_group_label>fluticasone high dose</arm_group_label>
    <arm_group_label>fluticasone medium &amp; low doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo matched for fluticasone propionate</intervention_name>
    <arm_group_label>fluticasone medium &amp; low doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female aged 40 years or more

          2. Severe to very severe chronic obstructive pulmonary disease (COPD)

          3. Current or ex-smoker with smoking history of at least 10 pack years

          4. At least one documented exacerbation of COPD in previous year

        Exclusion criteria:

          1. Significant diseases other than COPD; significant alcohol or drug abuse

          2. Current clinical diagnosis of asthma requiring steroid treatment

          3. History of thoracotomy with pulmonary resection

          4. Regular use of daytime oxygen

          5. Recent history (within 3 months) of myocardial infarction

          6. Recent (within 6 weeks) respiratory infection or COPD exacerbation

          7. Recent (within 6 weeks) treatment with systemic corticosteroids at doses in excess of
             5milligram / day

          8. Recent (within 3 months) unstable or life-threatening cardiac arrhythmia requiring
             intervention

          9. Recent (within 1 year) hospitalisation for cardiac failure

         10. Malignancy requiring chemotherapy or radiotherapy

         11. Clinical diagnosis of bronchiectasis

         12. Pregnant or nursing women

         13. Known hypersensitivity to study drugs

         14. Current or recent (within 30 days) participation in another clinical study

         15. Current participation in or recent completion (within 4 weeks) of a pulmonary
             rehabilitation program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>352.2046.61006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.61005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eupen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gilly</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jambes</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebbeke</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middelheim</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montigny-le-Tilleul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.32013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.55005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.55006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.55003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.35902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.35904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.35906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.35907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.35908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.35909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3317A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3317B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3317C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3320A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Castelnau le Lez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3320B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Castelnau le Lez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3320C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Castelnau le Lez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3335A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clermont Ferrand cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3314A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Forbach</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3333A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3326A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3326C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3325A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3325C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3325D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3334A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3324A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3332A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3332B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3332C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3331A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3331B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3331C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3329A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Laurent du Var</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3329B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Laurent du Var</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint-Pierre cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint-Pierre cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint-Pierre cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3302D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint-Pierre cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3336A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3336B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3336C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.3337A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cottbus</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donaustauf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Geesthacht</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gelnhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Immenhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cegled</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szarvas</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szazhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.36011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szigetszentmiklos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montescano (pv)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sesto S. Giovanni (mi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tradate (va)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.64007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auckland NZ</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.64003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.64004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.64006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newtown Wellington NZ</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.64005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Otahuhu New Zealand</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caloocan</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.63009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.63006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.63008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.63007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrow Wielkopolska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.48009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.48011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarnowskie Gory</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.48007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amanzimtoti</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tygerberg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barakaldo (Bilbao)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt (Girona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.88606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.88604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.88607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taiwan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.88608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taiwan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.2161A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.2162A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.2165A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.2164A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sousse</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.2163A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denizli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmit</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.38007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baillieston, Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barnsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cottingham, Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isleworth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>352.2046.44025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <results_first_submitted>December 23, 2014</results_first_submitted>
  <results_first_submitted_qc>February 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2015</results_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone Maintenance</title>
          <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone Withdrawal</title>
          <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1244"/>
                <participants group_id="P2" count="1244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1016">Includes open-label treatment if appropriate</participants>
                <participants group_id="P2" count="1011">Includes open-label treatment if appropriate</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="233"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS) which included all patients who were dispensed study medication and were documented to have taken ≥1 dose of randomised treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone Maintenance</title>
          <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
        </group>
        <group group_id="B2">
          <title>Fluticasone Withdrawal</title>
          <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1243"/>
            <count group_id="B2" value="1242"/>
            <count group_id="B3" value="2485"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="8.6"/>
                    <measurement group_id="B2" value="64.0" spread="8.4"/>
                    <measurement group_id="B3" value="63.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1013"/>
                    <measurement group_id="B2" value="1036"/>
                    <measurement group_id="B3" value="2049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Moderate or Severe On-treatment COPD Exacerbation</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as an increase or new onset of ≥2 lower respiratory symptoms related to COPD, with ≥1 symptom lasting ≥3 days, requiring a change in treatment. Lower respiratory symptoms included shortness of breath, sputum production (volume), sputum purulence, cough, wheezing and chest tightness. A change in treatment included: hospitalisation/treatment in an urgent care unit, prescription of antibiotics and/or systemic steroids or a significant change of prescribed respiratory medication such as theophyllines, long-acting beta-agonists or inhaled corticosteroids. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate or Severe On-treatment COPD Exacerbation</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as an increase or new onset of ≥2 lower respiratory symptoms related to COPD, with ≥1 symptom lasting ≥3 days, requiring a change in treatment. Lower respiratory symptoms included shortness of breath, sputum production (volume), sputum purulence, cough, wheezing and chest tightness. A change in treatment included: hospitalisation/treatment in an urgent care unit, prescription of antibiotics and/or systemic steroids or a significant change of prescribed respiratory medication such as theophyllines, long-acting beta-agonists or inhaled corticosteroids. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
          <population>Treated set</population>
          <units>days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.0" lower_limit="94.0" upper_limit="124.0"/>
                    <measurement group_id="O2" value="110.0" lower_limit="99.0" upper_limit="120.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Upper limit of 95% confidence interval (CI) &lt;1.2 indicates non-inferiority of Fluticasone withdrawal compared with Fluticasone maintenance</non_inferiority_desc>
            <p_value>0.3497</p_value>
            <p_value_desc>Two-sided p-value to test superiority of fluticasone maintenance over fluticasone withdrawal if non-inferiority shown.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Wald's chi-square test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.058</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.941</ci_lower_limit>
            <ci_upper_limit>1.189</ci_upper_limit>
            <estimate_desc>Ratio calculated as fluticasone withdrawal divided by fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Moderate or Severe On-treatment COPD Exacerbations</title>
        <description>Number of moderate or severe on-treatment COPD exacerbations, based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined and counted as moderate or severe if ≥1 of the contributing exacerbation events was moderate or severe. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital. Exacerbations were considered moderate if they required prescription of antibiotics and/or systemic steroids.
Measured values show adjusted mean event rate.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate or Severe On-treatment COPD Exacerbations</title>
          <description>Number of moderate or severe on-treatment COPD exacerbations, based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined and counted as moderate or severe if ≥1 of the contributing exacerbation events was moderate or severe. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital. Exacerbations were considered moderate if they required prescription of antibiotics and/or systemic steroids.
Measured values show adjusted mean event rate.</description>
          <population>Treated Set</population>
          <units>exacerbations per patient-year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.83" upper_limit="0.99"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.87" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4441</p_value>
            <method>Regression, Negative Binomial</method>
            <method_desc>Adjusted for log time at risk using log link function</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Ratio calculated as fluticasone withdrawal divided by fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With ≥1 Moderate or Severe On-treatment COPD Exacerbation</title>
        <description>Presence (yes vs no) of at least one moderate or severe on-treatment COPD exacerbation, displayed as a percentage. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital. Exacerbations were considered moderate if they required prescription of antibiotics and/or systemic steroids.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With ≥1 Moderate or Severe On-treatment COPD Exacerbation</title>
          <description>Presence (yes vs no) of at least one moderate or severe on-treatment COPD exacerbation, displayed as a percentage. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital. Exacerbations were considered moderate if they required prescription of antibiotics and/or systemic steroids.</description>
          <population>Treated set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2"/>
                    <measurement group_id="O2" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2269</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Severe On-treatment COPD Exacerbation</title>
        <description>Time to first severe on-treatment COPD exacerbation. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.
The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Severe On-treatment COPD Exacerbation</title>
          <description>Time to first severe on-treatment COPD exacerbation. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.
The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
          <population>Treated set</population>
          <units>days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not estimable as not enough events during the timeframe.</measurement>
                    <measurement group_id="O2" value="419.0" lower_limit="379.0">Not estimable as not enough events during the timeframe.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0849</p_value>
            <method>Chi-squared</method>
            <method_desc>Wald's chi-square test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.202</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.975</ci_lower_limit>
            <ci_upper_limit>1.481</ci_upper_limit>
            <estimate_desc>Ratio calculated as fluticasone withdrawal divided by fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Severe On-treatment COPD Exacerbations</title>
        <description>Number of severe on-treatment COPD exacerbations based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined and counted as severe if ≥1 of the contributing exacerbation events was severe. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.
Measured values show adjusted event rate.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Severe On-treatment COPD Exacerbations</title>
          <description>Number of severe on-treatment COPD exacerbations based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined and counted as severe if ≥1 of the contributing exacerbation events was severe. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.
Measured values show adjusted event rate.</description>
          <population>Treated set</population>
          <units>exacerbations per patient-year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.17" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0.19" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2291</p_value>
            <method>Regression, Negative Binomial</method>
            <method_desc>Adjusted for log time at risk using log link function</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
            <estimate_desc>Ratio calculated as fluticasone withdrawal divided by fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With at Least One Severe On-treatment COPD Exacerbation.</title>
        <description>Presence (yes vs no) of at least one severe on-treatment COPD exacerbation, displayed as a percentage. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With at Least One Severe On-treatment COPD Exacerbation.</title>
          <description>Presence (yes vs no) of at least one severe on-treatment COPD exacerbation, displayed as a percentage. Exacerbations were considered severe if the patient was held and treated for an acute respiratory condition in an urgent care department or an observation unit for &gt;6 hours, the patient was treated at home by a mobile urgent care team or the patient was admitted to hospital.</description>
          <population>Treated set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2083</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First On-treatment COPD Exacerbation</title>
        <description>Time to first on-treatment COPD exacerbation of any severity. The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First On-treatment COPD Exacerbation</title>
          <description>Time to first on-treatment COPD exacerbation of any severity. The &quot;measure type&quot; displays the 25th percentile and its 95% confidence interval.</description>
          <population>Treated set</population>
          <units>days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365.0" lower_limit="309.0">Not estimable as not enough events during the timeframe.</measurement>
                    <measurement group_id="O2" value="346.0" lower_limit="302.0">Not estimable as not enough events during the timeframe.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5562</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.035</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.923</ci_lower_limit>
            <ci_upper_limit>1.160</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of On-treatment COPD Exacerbations</title>
        <description>Number of on-treatment COPD exacerbations of any severity, based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined.
Measured values show adjusted event rate.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of On-treatment COPD Exacerbations</title>
          <description>Number of on-treatment COPD exacerbations of any severity, based on a 7-day gap rule: exacerbations where the onset date of the second exacerbation event was ≤7 days after the end date of the first exacerbation event were combined.
Measured values show adjusted event rate.</description>
          <population>Treated set</population>
          <units>exacerbations per patient-year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.95" upper_limit="1.12"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.99" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4342</p_value>
            <method>Regression, Negative binomial</method>
            <method_desc>Adjusted for log time at risk using log link function</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Ratio calculated as fluticasone withdrawal divided by fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With at Least One On-treatment COPD Exacerbation</title>
        <description>Presence (yes vs no) of at least one on-treatment COPD exacerbation of any severity, displayed as a percentage.</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With at Least One On-treatment COPD Exacerbation</title>
          <description>Presence (yes vs no) of at least one on-treatment COPD exacerbation of any severity, displayed as a percentage.</description>
          <population>Treated set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3155</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of On-treatment COPD Exacerbations</title>
        <description>Severity of on-treatment COPD exacerbations: for each patient, the worst applicable category was taken (i.e. none, mild, moderate or severe)</description>
        <time_frame>During randomised treatment, up to 488 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of On-treatment COPD Exacerbations</title>
          <description>Severity of on-treatment COPD exacerbations: for each patient, the worst applicable category was taken (i.e. none, mild, moderate or severe)</description>
          <population>Treated set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None and patient completed randomised treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None and patient discontinued randomised treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment Lung Function as Measured by Trough FEV1</title>
        <description>Change from baseline in on-treatment lung function as measured by trough forced expiratory volume in one second (FEV1); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 6, 12, 18 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment Lung Function as Measured by Trough FEV1</title>
          <description>Change from baseline in on-treatment lung function as measured by trough forced expiratory volume in one second (FEV1); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 visit (N=1135, 1135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009" spread="0.0062"/>
                    <measurement group_id="O2" value="-0.011" spread="0.0062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 visit (N=1114, 1092)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.0062"/>
                    <measurement group_id="O2" value="-0.018" spread="0.0063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 visit (N=1077, 1058)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.0064"/>
                    <measurement group_id="O2" value="-0.050" spread="0.0064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=970, 935)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.016" spread="0.0094"/>
                    <measurement group_id="O2" value="-0.059" spread="0.0096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.069</ci_lower_limit>
            <ci_upper_limit>-0.017</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in On-treatment Dyspnoea as Measured by the Modified Medical Research Council (MMRC) Dyspnoea Scale</title>
        <description>Change from baseline in on-treatment dyspnoea as measured by the Modified Medical Research Council (MMRC) dyspnoea scale; change was calculated as week score minus baseline score. Negative changes from baseline indicate an improvement in health.
Scale from 0 to 4:
0 = not troubled by breathlessness, except during strenuous exercise
1 = short of breath when hurrying or walking up a slight hill
2 = walks slower than contemporaries on the same level because of breathlessness, or has to stop for breath when walking at own pace
3 = stops for breath after approximately 100 yards, or after a few minutes on the level
4 = too breathless to leave the house, or breathless when dressing or undressing
&quot;No breathlessness&quot; was given a score of -1
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 18 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in On-treatment Dyspnoea as Measured by the Modified Medical Research Council (MMRC) Dyspnoea Scale</title>
          <description>Change from baseline in on-treatment dyspnoea as measured by the Modified Medical Research Council (MMRC) dyspnoea scale; change was calculated as week score minus baseline score. Negative changes from baseline indicate an improvement in health.
Scale from 0 to 4:
0 = not troubled by breathlessness, except during strenuous exercise
1 = short of breath when hurrying or walking up a slight hill
2 = walks slower than contemporaries on the same level because of breathlessness, or has to stop for breath when walking at own pace
3 = stops for breath after approximately 100 yards, or after a few minutes on the level
4 = too breathless to leave the house, or breathless when dressing or undressing
&quot;No breathlessness&quot; was given a score of -1
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18 visit (N=1140, 1143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.030" spread="0.022"/>
                    <measurement group_id="O2" value="-0.001" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=1043, 1019)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.028" spread="0.024"/>
                    <measurement group_id="O2" value="0.035" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0632</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment Physical Health Status as Determined by Body Mass Index (BMI)</title>
        <description>Change from baseline in on-treatment physical health status as determined by body mass index (BMI); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 18 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment Physical Health Status as Determined by Body Mass Index (BMI)</title>
          <description>Change from baseline in on-treatment physical health status as determined by body mass index (BMI); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>kg/m2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18 visit (N=1143, 1146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.028"/>
                    <measurement group_id="O2" value="0.040" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=1047, 1021)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.039"/>
                    <measurement group_id="O2" value="-0.009" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8137</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.013</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.122</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment Exercise Capacity Measured by Six-minute Walk Test (6-MWT)</title>
        <description>Change from baseline in on-treatment exercise capacity measured by six-minute walk test (6-MWT); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 18 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment Exercise Capacity Measured by Six-minute Walk Test (6-MWT)</title>
          <description>Change from baseline in on-treatment exercise capacity measured by six-minute walk test (6-MWT); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18 visit (N=1111, 1110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="1.993"/>
                    <measurement group_id="O2" value="1.94" spread="1.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=1013, 987)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="2.231"/>
                    <measurement group_id="O2" value="0.42" spread="2.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2663</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.170</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.74</ci_lower_limit>
            <ci_upper_limit>2.69</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment BODE Index</title>
        <description>Change from baseline in on-treatment BODE index (Body mass index, airflow Obstruction, Dyspnea and Exercise capacity index), a composite score ranging from 0 (best) to 10 (worst); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 18 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment BODE Index</title>
          <description>Change from baseline in on-treatment BODE index (Body mass index, airflow Obstruction, Dyspnea and Exercise capacity index), a composite score ranging from 0 (best) to 10 (worst); change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18 visit (N=1038, 1024)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.03"/>
                    <measurement group_id="O2" value="0.06" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=931, 907)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.04"/>
                    <measurement group_id="O2" value="0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Cough Impact Domain</title>
        <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Cough impact domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from “not at all/never” to “extremely/always” on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less impact due to cough.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 12, 18 and 52 visits</time_frame>
        <population>Treated set who completed CASA-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Cough Impact Domain</title>
          <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Cough impact domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from “not at all/never” to “extremely/always” on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less impact due to cough.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set who completed CASA-Q</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 visit (N=307, 319)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="0.986"/>
                    <measurement group_id="O2" value="-1.24" spread="0.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 visit (N=302, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" spread="1.035"/>
                    <measurement group_id="O2" value="-3.71" spread="1.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=268, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.51" spread="1.063"/>
                    <measurement group_id="O2" value="-5.54" spread="1.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4914</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.499</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.98</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Cough Symptoms Domain</title>
        <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Cough symptoms domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from “not at all/never” to “a lot/always” on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less symptoms due to cough.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 12, 18 and 52 visits</time_frame>
        <population>Treated set who completed CASA-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Cough Symptoms Domain</title>
          <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Cough symptoms domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from “not at all/never” to “a lot/always” on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less symptoms due to cough.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set who completed CASA-Q</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 visit (N=309, 318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="1.062"/>
                    <measurement group_id="O2" value="-0.85" spread="1.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 visit (N=305, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.103"/>
                    <measurement group_id="O2" value="-3.34" spread="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=270, 268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="1.180"/>
                    <measurement group_id="O2" value="-3.26" spread="1.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3490</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.669</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.84</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Sputum Impact Domain</title>
        <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Sputum impact domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from “not at all/never” to “a lot/always” on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less impact due to sputum.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 12, 18 and 52 visits</time_frame>
        <population>Treated set who completed CASA-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Sputum Impact Domain</title>
          <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Sputum impact domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from “not at all/never” to “a lot/always” on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less impact due to sputum.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set who completed CASA-Q</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 visit (N=308, 317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="0.996"/>
                    <measurement group_id="O2" value="-1.63" spread="0.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 visit (N=303, 310)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="0.977"/>
                    <measurement group_id="O2" value="-3.31" spread="0.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=267, 267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.29" spread="1.047"/>
                    <measurement group_id="O2" value="-4.15" spread="1.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9262</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.480</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.77</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Sputum Symptoms Domain</title>
        <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Sputum symptoms domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from “not at all/never” to “extremely/always” on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less symptoms due to sputum.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 12, 18 and 52 visits</time_frame>
        <population>Treated set who completed CASA-Q</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Sputum Symptoms Domain</title>
          <description>Change from baseline in on-treatment cough and expectoration as measured by the cough and sputum assessment questionnaire (CASA-Q) (selected sites only): Sputum symptoms domain. Change was calculated as week score minus baseline score. Response options for the items in this domain range from “not at all/never” to “extremely/always” on a five-point scale. Domain items were reverse scored, summed and transformed to a domain score ranging from 0 to 100 where a higher score is associated with less symptoms due to sputum.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set who completed CASA-Q</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 visit (N=308, 317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="1.154"/>
                    <measurement group_id="O2" value="-1.24" spread="1.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 visit (N=302, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="1.119"/>
                    <measurement group_id="O2" value="-1.93" spread="1.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=269, 268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.10" spread="1.212"/>
                    <measurement group_id="O2" value="-2.45" spread="1.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1241</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.716</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>6.01</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment FEV1 as Measured by Home Based Spirometry</title>
        <description>Change from baseline in on-treatment Forced Expiratory Volume in One Second (FEV1) as measured by home based spirometry. Change was calculated as week score minus baseline score. The weekly mean was defined as the mean of the measurements taken during the last 7 days prior to the visit date, and was calculated if ≥4 of the 7 days had non-missing measurements. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 6, 12, 18, 27, 36, 45 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment FEV1 as Measured by Home Based Spirometry</title>
          <description>Change from baseline in on-treatment Forced Expiratory Volume in One Second (FEV1) as measured by home based spirometry. Change was calculated as week score minus baseline score. The weekly mean was defined as the mean of the measurements taken during the last 7 days prior to the visit date, and was calculated if ≥4 of the 7 days had non-missing measurements. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 visit (N=893, 939)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.0066"/>
                    <measurement group_id="O2" value="-0.053" spread="0.0065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 visit (N=910, 930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.050" spread="0.0068"/>
                    <measurement group_id="O2" value="-0.056" spread="0.0067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 visit (N=913, 901)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.0068"/>
                    <measurement group_id="O2" value="-0.093" spread="0.0068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 27 visit (N=863, 843)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.0071"/>
                    <measurement group_id="O2" value="-0.092" spread="0.0072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 visit (N=854, 845)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.059" spread="0.0074"/>
                    <measurement group_id="O2" value="-0.099" spread="0.0074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 45 visit (N=830, 815)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.061" spread="0.0080"/>
                    <measurement group_id="O2" value="-0.103" spread="0.0080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=785, 788)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.067" spread="0.0087"/>
                    <measurement group_id="O2" value="-0.115" spread="0.0087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0123</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.073</ci_lower_limit>
            <ci_upper_limit>-0.024</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment FVC as Measured by Home Based Spirometry</title>
        <description>Change from baseline in on-treatment forced vital capacity (FVC) as measured by home based spirometry. Change was calculated as week score minus baseline score. The weekly mean was defined as the mean of the measurements taken during the last 7 days prior to the visit date, and was calculated if ≥4 of the 7 days had non-missing measurements. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 6, 12, 18, 27, 36, 45 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment FVC as Measured by Home Based Spirometry</title>
          <description>Change from baseline in on-treatment forced vital capacity (FVC) as measured by home based spirometry. Change was calculated as week score minus baseline score. The weekly mean was defined as the mean of the measurements taken during the last 7 days prior to the visit date, and was calculated if ≥4 of the 7 days had non-missing measurements. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 visit (N=893, 939)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.116" spread="0.0179"/>
                    <measurement group_id="O2" value="-0.089" spread="0.0177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 visit (N=910, 930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.113" spread="0.0168"/>
                    <measurement group_id="O2" value="-0.105" spread="0.0167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 visit (N=913, 901)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.122" spread="0.0177"/>
                    <measurement group_id="O2" value="-0.124" spread="0.0177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 27 visit (N=863, 843)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.123" spread="0.0167"/>
                    <measurement group_id="O2" value="-0.147" spread="0.0167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 visit (N=854, 845)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.135" spread="0.0170"/>
                    <measurement group_id="O2" value="-0.158" spread="0.0171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 45 visit (N=830, 815)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.141" spread="0.0174"/>
                    <measurement group_id="O2" value="-0.168" spread="0.0175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=785, 788)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.157" spread="0.0180"/>
                    <measurement group_id="O2" value="-0.201" spread="0.0180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0855</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0255</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.094</ci_lower_limit>
            <ci_upper_limit>0.006</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment PEFR as Measured by Home Based Spirometry</title>
        <description>Change from baseline in on-treatment peak expiratory flow rate (PEFR) as measured by home based spirometry; change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 6, 12, 18, 27, 36, 45 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment PEFR as Measured by Home Based Spirometry</title>
          <description>Change from baseline in on-treatment peak expiratory flow rate (PEFR) as measured by home based spirometry; change was calculated as week score minus baseline score. Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>Litres/sec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 visit (N=893, 939)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.228" spread="0.0249"/>
                    <measurement group_id="O2" value="-0.230" spread="0.0246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 visit (N=910, 930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.266" spread="0.0253"/>
                    <measurement group_id="O2" value="-0.290" spread="0.0252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 visit (N=913, 901)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.295" spread="0.0253"/>
                    <measurement group_id="O2" value="-0.435" spread="0.0254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 27 visit (N=863, 843)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.319" spread="0.0273"/>
                    <measurement group_id="O2" value="-0.430" spread="0.0274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 visit (N=854, 845)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.352" spread="0.0278"/>
                    <measurement group_id="O2" value="-0.473" spread="0.0278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 45 visit (N=830, 815)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.368" spread="0.0297"/>
                    <measurement group_id="O2" value="-0.490" spread="0.0298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=785, 788)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.377" spread="0.0318"/>
                    <measurement group_id="O2" value="-0.538" spread="0.0318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0450</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.249</ci_lower_limit>
            <ci_upper_limit>-0.073</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Activity Domain</title>
        <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Activity domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 27 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Activity Domain</title>
          <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Activity domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 27 visit (N=1002, 988)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.492"/>
                    <measurement group_id="O2" value="0.85" spread="0.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=942, 916)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.512"/>
                    <measurement group_id="O2" value="0.78" spread="0.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1838</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.728</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Impact Domain</title>
        <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Impact Domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 27 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Impact Domain</title>
          <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Impact Domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 27 visit (N=1004, 998)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.456"/>
                    <measurement group_id="O2" value="0.35" spread="0.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=946, 921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.494"/>
                    <measurement group_id="O2" value="1.27" spread="0.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0551</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.702</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Symptoms Domain</title>
        <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Symptoms domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 27 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Symptoms Domain</title>
          <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Symptoms domain. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 27 visit (N=1010, 998)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.583"/>
                    <measurement group_id="O2" value="0.62" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=955, 921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.593"/>
                    <measurement group_id="O2" value="1.11" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4804</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.845</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Total Score</title>
        <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Total score. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 27 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Total Score</title>
          <description>Change from baseline in on-treatment St Georges Respiratory Questionnaire (SGRQ) scores: Total score. Scores range from 0 to 100, with higher scores indicating more limitations. Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 27 visit (N=996, 986)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.398"/>
                    <measurement group_id="O2" value="0.55" spread="0.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=939, 913)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.432"/>
                    <measurement group_id="O2" value="1.15" spread="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0467</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.614</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in On-treatment Physician Global Evaluation</title>
        <description>Change from baseline in on-treatment physician global evaluation. The evaluation reflected the physician's opinion of the patient's overall condition and was based on the need for concomitant medication, the number and severity of exacerbations, the severity of cough, the ability to exercise, the amount of wheezing and any other relevant clinical observations. Patients were graded on a scale of 1 (poor) to 8 (excellent). Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
        <time_frame>Baseline and week 27 and 52 visits</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Maintenance</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Withdrawal</title>
            <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in On-treatment Physician Global Evaluation</title>
          <description>Change from baseline in on-treatment physician global evaluation. The evaluation reflected the physician's opinion of the patient's overall condition and was based on the need for concomitant medication, the number and severity of exacerbations, the severity of cough, the ability to exercise, the amount of wheezing and any other relevant clinical observations. Patients were graded on a scale of 1 (poor) to 8 (excellent). Change was calculated as week score minus baseline score.
Statistical analysis results are presented only for the week 52 visit as this is the primary timepoint of interest.</description>
          <population>Treated set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 27 visit (N=1113, 1093)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.03"/>
                    <measurement group_id="O2" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 visit (N=1041, 1014)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.03"/>
                    <measurement group_id="O2" value="0.08" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0223</p_value>
            <method>Restricted maximum likelihood</method>
            <method_desc>Repeated measures restricted maximum likelihood</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
            <estimate_desc>Difference calculated as fluticasone withdrawal minus fluticasone maintenance</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomised treatment plus 30 days post-treatment for patients not switching to open-label, up to 518 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone Maintenance</title>
          <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d., 50 μg salmeterol b.i.d.,and 500 μg fluticasone b.i.d. for 52 weeks (randomised treatment period).</description>
        </group>
        <group group_id="E2">
          <title>Fluticasone Withdrawal</title>
          <description>18μg tiotropium administered by oral inhalation once daily (q.d.), 50μg salmeterol and 500μg fluticasone, each administered by oral inhalation twice daily (b.i.d) for 6 weeks (open-label run in period), followed by 18 μg tiotropium q.d.and 50 μg salmeterol b.i.d. for 52 weeks, in combination with a stepwise withdrawal of fluticasone, consisting of 250μg fluticasone b.i.d for 6 weeks, followed by 100μg fluticasone b.i.d for 6 weeks, followed by placebo for 40 weeks (randomised treatment period).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="292" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="300" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bronchitis chemical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Urethral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia benign monoclonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Maxillofacial sinus neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Vocal cord neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cerebral microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Meningorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Radiculitis cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Mesangioproliferative glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Bullous lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Laryngeal leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Oxygen supplementation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="464" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="458" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="410" subjects_at_risk="1243"/>
                <counts group_id="E2" subjects_affected="413" subjects_at_risk="1242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information&quot;.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

